secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2022-03-22T23:59:59+00:00
Accession:  0001104659-22-036359
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma FY2021 net loss $12.9M; IPO raised $16M; CFO replaced
---------------------------------------------------------------------

- Net loss of $12.9M for FY2021, including $7.0M upfront license payments and $1.9M non-cash equity compensation.
- Cash and equivalents $5.7M at Dec 31, 2021; $16M gross IPO proceeds in Feb 2022 not included.
- Phase 1a trial for NXP800 (HSF1 inhibitor) initiated Dec 2021; IND-enabling studies for NXP900 ongoing.
- Michael Carson appointed VP of Finance, replacing interim CFO Uri Ben-Or; Carson is a CPA with biotech finance experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/0001104659-22-036359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465922036359/tm229925d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-036359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer